Skip to main content
. Author manuscript; available in PMC: 2024 Feb 15.
Published in final edited form as: J Immunol. 2023 Feb 15;210(4):486–495. doi: 10.4049/jimmunol.2200120

Figure 1. Recipient IL-12Rβ2 is required for development of aGVHD.

Figure 1.

Lethally irradiated BALB/c mice (650cGy) were transplanted with 5×106 T-cell depleted (TCD)-BM alone (BMA, n=5) or plus 0.75–1×106 purified T cells from WT (n=11) and IL-12Rβ2KO (n=10) mice on C57BL/6 (B6) background. Recipients were monitored for survival (A) and body weight loss (B) until 80 days post BMT. Lethally irradiated WT and IL-12Rβ2KO B6 mice (1100cGy) were transplanted with 5×106 TCD-BM alone (n=9) or plus 1×106 purified T cells (n=46) isolated from FVB mice. Recipients were monitored for (C) survival and (D) body weight loss until 80 days post BMT. Data shown are from 2 for A, B or are from 5 repeated experiments for C, D. Log-rank (Mantel-Cox) test (A and C) was used for comparison of survival between groups. Nonparametric Mann-Whitney U test (B and D) was used to compare body weight loss between groups. Statistical data were presented as mean ± 1SD; significance was determined by Student’s t test. *** p < 0.001.